Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>To me its a 50% reduction in Tyzeka cost to the end user, a product availability problem or a hold back of product thats reflecting low sales revenues.<

1. There was a lack of product for the first four months after the October 2006 FDA approval due to a delay in having the FDA approve the marketing materials. (Was this sloppy execution or intentional? I don’t know.)

2. The Tyzeka price discount to Baraclude is in the 20-30% range (not 50%). Almost all observers in the field thought that Baraclude was priced too high when it came out and that this hindered its early uptake.